Repligen builds in cell therapy with $1.5bn BioLife takeover
Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Newsletters and Deep Dive digital magazine
Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Early diagnosis only changes outcomes if it is followed by timely treatment.
Celcuity has won FDA approval for gedatolisib – its first product – as a treatment for patients with a particular form of breast cancer.
A study has shown that, for people living with advanced cancer, a weekly remote check-in with the care team can have a significant impact on outcomes.
Editor's Picks
Newsletters and Deep Dive
digital magazine